Flotetuzumab Expanded Access Program

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

NCT04582864 ·Status: TERMINATED ·Phase: PHASE2

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

NCT04714372 ·Status: COMPLETED ·Phase: PHASE1

flt3L in Treating Patients With Acute Myeloid Leukemia

NCT00006223 ·Status: COMPLETED ·Phase: PHASE3

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

NCT03739606 ·Status: WITHDRAWN ·Phase: PHASE2

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

NCT04158739 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

NCT06786533 ·Status: RECRUITING ·Phase: PHASE1

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

NCT06366789 ·Status: RECRUITING ·Phase: PHASE1

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

NCT02152956 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia

NCT07087847 ·Status: NOT_YET_RECRUITING ·Phase: NA

Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)

NCT00909168 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study of FMT in Patients With AML Allo HSCT in Recipients

NCT03678493 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

NCT05593185 ·Status: AVAILABLE

Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01701323 ·Status: TERMINATED ·Phase: PHASE1

AML Therapy With Irradiated Allogeneic Cells

NCT02105116 ·Status: TERMINATED ·Phase: NA

Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia

NCT01991457 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

NCT02312037 ·Status: NO_LONGER_AVAILABLE

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

NCT03245424 ·Status: APPROVED_FOR_MARKETING

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

NCT04217356 ·Status: ACTIVE_NOT_RECRUITING

Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT00394381 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT

NCT03696537 ·Status: TERMINATED ·Phase: PHASE1

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

NCT00146120 ·Status: COMPLETED ·Phase: PHASE3

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

NCT00303667 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation

NCT01483274 ·Status: WITHDRAWN ·Phase: PHASE1

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia

NCT00100971 ·Status: TERMINATED ·Phase: PHASE1

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT03224819 ·Status: TERMINATED ·Phase: EARLY_PHASE1